R66
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 21
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.430
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- NOTCH_SIGNALING+0.400
- TNFA_SIGNALING_VIA_NFKB+0.360
- P53_PATHWAY+0.340
- HEDGEHOG_SIGNALING+0.330
- TGF_BETA_SIGNALING+0.330
- APICAL_JUNCTION+0.320
- INTERFERON_ALPHA_RESPONSE+0.310
- WNT_BETA_CATENIN_SIGNALING+0.310
Top 10 suppressed
- E2F_TARGETS-0.530
- G2M_CHECKPOINT-0.480
- MYC_TARGETS_V1-0.460
- MYC_TARGETS_V2-0.460
- SPERMATOGENESIS-0.280
- PANCREAS_BETA_CELLS-0.240
- ANDROGEN_RESPONSE-0.230
- KRAS_SIGNALING_DN-0.170
- MITOTIC_SPINDLE-0.140
- FATTY_ACID_METABOLISM-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR13311162 | — | — | 0.866 |
| 2 | TCGA-64-5815-01A-01R-1628-07 | — | cohortA1 | 0.850 |
| 3 | SRR10842367 | — | — | 0.844 |
| 4 | TCGA-FD-A3SQ-01A-21R-A22U-07 | — | — | 0.843 |
| 5 | MDT-AP-1369 | Med | Medulloblastoma | 0.840 |
| 6 | SRR13780273 | — | cohortMD2 | 0.831 |
| 7 | SRR8392884 | — | cohortA1 | 0.828 |
| 8 | c2ccc6b3-34d8-47c5-9367-cc53aad1622e | — | — | 0.825 |
| 9 | ERR2208941 | — | — | 0.824 |
| 10 | BSR_03_0053_A6_S70 | — | A | 0.821 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.430 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.400 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.360 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.340 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.330 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.330 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.320 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.310 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.310 | Inavolisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.290 | Binimetinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.290 | Inavolisib | — uncovered |
| APOPTOSIS | 0.270 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.250 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.240 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.240 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.200 | Inavolisib | — uncovered |